Abstract
Two polyoxometalate-phosphonate compounds with the formular (TBA)2(Hbiz)2 [(C3H5O2P)2Mo5O21]•05H2O (1) and [Ni(2,2′bpy)3]2[(C6H5P)2Mo5O21]•3H2O (2) (TBA=tetrabutylammonium, biz=benzimidazole, bpy=bipyridine) have been synthesized under hydrothermal condition and structurally determined by single-crystal X-ray diffraction. Compound 1 and 2 are Strandberg-type polyoxometalate. The compounds were characterized by various means containing elemental analysis, PXRD, IR and thermal gravimetric analysis. Additionally, their photocatalytic degradation properties toward rhodamine-B are investigated. Compound 2 as catalyst has higher photocatalytic degradation of RhB than 1 due to its larger porosity. Results of the experiment on antitumor activities in vitro showed that two compounds inhibited five different human cancer cells (gastric cancer cells, HGC-27 and SNU668; liver cancer cells, Huh7; and colon cancer cells, HCT116 and SW480) demonstrated dose dependency and selectivity. The relationship between structure and biology activity indicate that inorganic and organic segments may influence the antitumor activity, the introduction of biz and 3-phosphonopropionic acid into P2Mo5 can make compound 1 better antitumor activities.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.